Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche

Reuters

Nov 25, 2025

<a href="https://laohu8.com/S/LINE">Lineage</a> Cell <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Achieves Milestone in Collaboration with Genentech and Roche

Lineage Cell Therapeutics Inc. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration $(AMD)$. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2586496407"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586496407\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586496407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 00:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586496407","market":"nz","top_or_hot":-1,"title":"Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LINE\">Lineage</a> Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Achieves Milestone in Collaboration with Genentech and Roche\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LCTX\">Lineage Cell Therapeutics Inc</a>. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 00:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LINE\">Lineage</a> Cell <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Achieves Milestone in Collaboration with Genentech and Roche\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LCTX\">Lineage Cell Therapeutics Inc</a>. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLbqqtYz:1","article_id":"2586496407","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586496407","pubTimestamp":1764001508,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lineage Cell Therapeutics Inc. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen , a suspension of human allogeneic retinal pigment epithelial  cells aimed at treating geographic atrophy  secondary to dry age-related macular degeneration . Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LCTX":"Lineage Cell Therapeutics Inc"},"translate_title":"Lineage Cell Therapeutics与基因泰克和罗氏合作实现里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LCTX":0.9},"content_text":"Lineage Cell Therapeutics Achieves Milestone in Collaboration with Genentech and Roche\n    \n\nLineage Cell Therapeutics Inc. has entered into a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the development of OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells aimed at treating geographic atrophy (GA) secondary to dry age-related macular degeneration $(AMD)$. Lineage recently announced the achievement of the first milestone under this collaboration, which is tied to manufacturing and clinical advancements in the OpRegen cell therapy program. The partnership includes potential milestone payments totaling up to $620 million and involves an exclusive global development effort currently being evaluated in a Phase 2a clinical study.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}